Loading…

InMode Ltd.INMDCompetitor analysis, valuation and peers

United States · USD·Health Care›Medical Specialties
Momentum weak 37
Mkt cap
$741M
US dollars, full cap
Free float
84%
of shares outstanding
$/day
$8.62M
20-day average traded
Fwd P/E
9.8×
forward earnings
ROIC−WACC
+21.7 pp
WACC 14.9%
Hurdle
-23 pp
Req g minus delivered
Next earnings
84 days
10 Feb 2027
Close · USD$12.88
1D-0.3%
1W-6.2%
1M-8.9%
3M-13.7%
6M-8.1%
YTD-12.3%
1Y-7.4%
ATR %2.7%
Beta0.70
52w lowhigh22.7% off high

What InMode does

Employees: 660

InMode at a glance

Size InMode (INMD) is a United States Health Care company (Medical Specialties) with a market value of $741M, the 2423rd largest of 3,085 United States companies the cockpit tracks. Shares closed at $12.88 on 18 Nov 2026.

Performance Over six months the shares fell 8.1%, against -16.3% for the median peer and -2.2% for the United States market (cap-weighted) — 9th highest of 21 in its peer set.

Growth Revenue grew 2.5% over the last twelve months (peer median +13.0%); the operating margin is 17.6% (peer median 13.1%).

Valuation It trades at 9.8× forward earnings against a peer median of 19.9× (cheapest of 16).

Price implies For today's price to make sense, revenue must grow about -11% a year for seven years (Req g). Recent delivered growth is +12%, so the hurdle is -23 pp: the price already allows for a slowdown.

Capital Return on invested capital runs 21.7 points above its cost of capital (14.9% WACC).

Short interest Short interest is 4.0% of the free float (30 Oct 2026).

Next results Next results expected around 10 Feb 2027 (exchange calendar; dates can move).

Relative performance

9010011021 May 202621 Aug 202618 Nov 2026INMD 93Peer median 85
Six months, rebased to 100: InMode against the median of its 20 peers (local-currency closes).

InMode financials

Reported figures in USD; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
Revenue$374M$370M$395M$492M$454M
Revenue growth—-6%-20%+8%—
Gross profit$286M$291M$317M$411M$381M
EBITDA$66.6M$86.1M$113M$196M$199M
Net income$74.5M$93.8M$181M$198M$162M
Free cash flow$71.8M$84.3M$132M$176M$180M
Capital expenditure$1.15M$972,000$669,000$705,000$1.57M
Total debt$3.58M$8.23M$7.82M$9.02M$4.96M

Quarterly statements and history in the cockpit →

InMode competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

-50%0%+50%-20%-10%0%+10%6031086008553004533013676881790029503004633011222190VREX1302300622CTKBMLAB688410BBNX7575SETL1501INMD6-month return →1-month return →
Up and to the right = strong over both horizons. InMode is the large dot.

Fundamentals: revenue growth against valuation

0%+20%+40%+60%0×200×400×603108300453301367688179688108300463301122VREX1302688410INMDRevenue growth (TTM) →Forward P/E →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. InMode is the large dot.

Capital: growth delivered against growth the price implies

0%+50%+100%0%50%100%603108300453301367688179688108300463219013027575INMDGrowth delivered (Del g) →Growth the price implies (Req g, 7 yrs) →
Above the diagonal = the price needs more growth than the company has been delivering; below = the price already allows for a slowdown. InMode is the large dot.

InMode competitors and peer comparison

How InMode compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

InMode against its 20 peers (data as of 18 Nov 2026)
MeasureINMDPeer medianRank in peer set
1-month return-8.9%-6.7%10th lowest of 21
6-month return-8.1%-16.3%9th highest of 21
Distance from 52-week high-22.7%-39.8%8th highest of 21
Revenue growth (TTM)+2.5%+13.0%6th lowest of 21
Operating margin17.6%13.1%8th highest of 21
Forward P/E9.8×19.9×cheapest of 16
Growth the price implies (Req g, 7 yrs)-10.8%7.9%least demanding of 14
Growth delivered (Del g)+12.4%+15.5%6th lowest of 14
Hurdle (Req g minus delivered)-23.2 pp-9.8 pp3rd least demanding of 14
ROIC minus cost of capital+21.7 pp-0.3 pp2nd highest of 21
EV / EBITDA3.5×12.7×cheapest of 8
Net debt / EBITDA-7.7×-0.6×least indebted of 8

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginForward P/EReq gDelivered g
InMode INMDUnited States$741M-8%+2%18%9.8×-10.8%+12.4%
Shanghai Runda Medical Technology 603108.SSChina$744M-36%-12%-2%20.5×20.3%-0.2%
Beijing Aerospace Changfeng 600855.SSChina$738M-44%-10%-19%n/an/an/a
Jiang Xi Sanxin Medtec 300453.SZChina$744M-3%+12%18%16.2×-1.9%+11.8%
BMC Medical 301367.SZChina$737M-17%+37%17%18.7×-1.5%+15.6%
Shanghai Aladdin Biochemical Technology 688179.SSChina$736M-37%+39%24%27.4×17.1%+24.2%
Allmed Medical Products 002950.SZChina$747M-32%+14%8%n/an/an/a
Sino Medical Sciences Technology 688108.SSChina$753M-41%+22%19%60.0×27.9%+9.9%
Maccura Biotechnology 300463.SZChina$756M-18%-1%-4%421.0×7.9%-10.2%
Caina Technology 301122.SZChina$721M+36%+61%0%55.4×n/an/a
Zylox-Tonbridge Medical Technology 2190.HKHong Kong$768M-16%+39%25%14.4×3.8%+105.8%
Varex Imaging VREXUnited States$771M+79%+5%8%19.9×n/an/a
LifeTech Scientific 1302.HKHong Kong$771M-30%+1%12%19.8×9.6%+15.5%
Doctorglasses Chain 300622.SZChina$710M-22%+6%14%22.8×-3.4%+15.7%
Cytek Biosciences CTKBUnited States$774M+57%+6%-21%n/an/an/a
Mesa Laboratories MLABUnited States$775M+33%+2%10%11.5×21.3%+13.2%
SWS Hemodialysis Care 688410.SSChina$706M-11%+31%19%23.5×16.2%+25.9%
Beta Bionics BBNXUnited States$779M+42%+44%-73%n/an/an/a
Japan Lifeline 7575.TJapan$703M+34%+6%19%14.5×-9.5%+2.9%
Standard Engineering Technology SETL.NSIndia$783M+168%+45%14%n/an/an/a
Shanghai INT Medical Instruments 1501.HKHong Kong$700M-25%+35%21%15.9×-3.3%+23.5%

Questions

Which companies are InMode's closest peers?
The cockpit's peer set: Shanghai Runda Medical Technology (603108.SS), Beijing Aerospace Changfeng (600855.SS), Jiang Xi Sanxin Medtec (300453.SZ), BMC Medical (301367.SZ), Shanghai Aladdin Biochemical Technology (688179.SS), Allmed Medical Products (002950.SZ), Sino Medical Sciences Technology (688108.SS), Maccura Biotechnology (300463.SZ).
Is InMode expensive compared with its peers?
On forward p/e it trades at 9.8× against a peer median of 19.9×, cheapest of 16 in its peer set. For today's price to make sense, revenue must grow about -11% a year for seven years (Req g). Recent delivered growth is +12%, so the hurdle is -23 pp: the price already allows for a slowdown.
How has InMode stock performed?
Over six months to 18 Nov 2026 the shares returned -8.1% against -16.3% for the median peer; over one year -7.4%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.